<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146168">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01729286</url>
  </required_header>
  <id_info>
    <org_study_id>TEI-007</org_study_id>
    <nct_id>NCT01729286</nct_id>
  </id_info>
  <brief_title>Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix</brief_title>
  <acronym>HEALED</acronym>
  <official_title>A Multi-Center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold Moist Wound Therapy and Standard of Care Moist Wound Therapy for the Treatment of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TEI Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TEI Biosciences Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the effectiveness of PriMatrix Moist Wound Therapy
      (MWT) with Standard of Care MWT for the treatment of chronic diabetic foot ulcers in
      subjects with diabetes mellitus and without significantly compromised arterial circulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multi-center, prospective, randomized single-blinded study evaluating
      the efficacy of PriMatrix MWT versus Standard of Care MWT in achieving complete wound
      closure of chronic diabetic foot ulcers by 12 weeks (84 days). To measure wound recidivism
      and changes in functional quality of life, each subject will complete the Cardiff Wound
      Impact Schedule and the SF-36v2™ at three time points during the study i) at initial
      screening, ii) at completion of treatment phase, and iii)at 24 weeks (post-randomization).
      Additionally, the data obtained from the SF-36v2™ will be used in an economic evaluation of
      the treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete wound closure</measure>
    <time_frame>by 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in predicted medical expenditures between PriMatrix and Standard of Care</measure>
    <time_frame>over 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life measurements between PriMatrix and Standard of Care</measure>
    <time_frame>between baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonserious and serious adverse events</measure>
    <time_frame>over 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>PriMatrix Moist Wound Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Moist Wound Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PriMatrix Moist Wound Therapy</intervention_name>
    <description>sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading</description>
    <arm_group_label>PriMatrix Moist Wound Therapy</arm_group_label>
    <other_name>PriMatrix Dermal Repair Scaffold</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care Moist Wound Therapy</intervention_name>
    <description>sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading</description>
    <arm_group_label>PriMatrix Moist Wound Therapy</arm_group_label>
    <arm_group_label>Standard of Care Moist Wound Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I or Type II diabetes

          -  A diabetic foot ulcer located on the foot or ankle at least one square centimeter

        Exclusion Criteria:

          -  Suspected or confirmed signs/symptoms of wound infection

          -  Hypersensitivity to bovine collagen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Kavros, DPM</last_name>
    <role>Study Director</role>
    <affiliation>TEI Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan M Wilson, MSN, MHA, RN</last_name>
    <phone>7065048997</phone>
    <email>joan.wilson@primatrix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allen Lau, BS</last_name>
    <phone>6172681616</phone>
    <phone_ext>257</phone_ext>
    <email>allen.lau@primatrix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Hamm</last_name>
      <phone>323-442-8831</phone>
      <email>rose.hamm@health.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Health Network</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Winters, DPM</last_name>
      <phone>317-208-3890</phone>
      <email>soledoc1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Winters, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foot &amp; Andle Center of Mooresville</name>
      <address>
        <city>Mooresville</city>
        <state>Indiana</state>
        <zip>46158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Neville</last_name>
      <phone>317-460-4546</phone>
      <email>stacineville@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Scott Neville, DPM</last_name>
      <phone>3174604546</phone>
      <email>smneville@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Neville, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Vascular</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wharton</last_name>
      <phone>816-872-1598</phone>
      <email>swharton@kcvascular.com</email>
    </contact>
    <investigator>
      <last_name>Karl Stark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anthony's Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Dietzler-Otte</last_name>
      <phone>314-299-6043</phone>
      <email>janette.dietzler@samcstl.org</email>
    </contact>
    <investigator>
      <last_name>Perry Giestler, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Sollecito, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Comprehensive Wound Healing Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Kaplan</last_name>
      <phone>516-562-4578</phone>
      <email>Skaplan2@NSHS.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jaewon Chung</last_name>
      <phone>5165624578</phone>
      <email>jchung2@nshs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alicia Oropallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Stevens, BSN</last_name>
      <phone>740-689-4426</phone>
      <email>lisas@fmchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Andy Bhatia, DPM</last_name>
      <phone>7406894426</phone>
      <email>asbhatia@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andy Bhatia, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Podiatrico del Norte</name>
      <address>
        <city>Arecibo</city>
        <zip>00612</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mattei, MD, DPM</last_name>
      <phone>787-880-2954</phone>
      <email>centropodiatricodelnorte@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Mattei, MD, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renier Gonzalez-Cruz</name>
      <address>
        <city>Juana Diaz</city>
        <zip>00795</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renier Gonzalez, MD</last_name>
      <phone>787-260-1005</phone>
      <email>gonzalezcruzmdoffice@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aimee Gonzalez</last_name>
      <phone>872601005</phone>
      <email>aymee_98@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Renier Gonzalez-Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
